Repligen Corp (RGEN): Cash & Equivalents
$566.02M
As of 2025-12-31
$606.78M
As of 2026-06-30
+2.6%
3-year compound annual growth
-4.6%
5-year compound annual growth
+26.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $566.02M | -25.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $757.36M | +0.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $751.32M | +43.5% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $523.46M | -13.3% | 2024-11-18, Balance as of period end |
| 2021-12-31 | $603.81M | -15.8% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $717.29M | +35.7% | 2022-02-17, Balance as of period end |
| 2019-12-31 | $528.39M | +172.6% | 2022-02-17, Balance as of period end |
| 2018-12-31 | $193.82M | +11.5% | 2021-02-24, Balance as of period end |
| 2017-12-31 | $173.76M | +42.2% | 2020-02-26, Balance as of period end |
| 2016-12-31 | $122.23M | +126.0% | 2019-03-01, Balance as of period end |
| 2015-12-31 | $54.09M | +53.0% | 2018-02-22, Balance as of period end |
| 2014-12-31 | $35.36M | -11.2% | 2017-02-23, Balance as of period end |
| 2013-12-31 | $39.83M | +36.4% | 2016-02-25, Balance as of period end |
| 2012-12-31 | $29.21M | +161.6% | 2015-03-17, Balance as of period end |
| 2011-12-31 | $11.17M | n/a | 2014-03-14, Balance as of period end |
| 2011-03-31 | $14.20M | n/a | 2013-03-15, Balance as of period end |
| 2010-12-31 | $9.79M | n/a | 2014-03-14, Balance as of period end |
| 2010-03-31 | $12.53M | n/a | 2012-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $183.64M | +93.7% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗